Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
Overview
- Phase
- Phase 1
- Intervention
- Placebo
- Conditions
- Pain
- Sponsor
- New York State Psychiatric Institute
- Enrollment
- 26
- Locations
- 1
- Primary Endpoint
- Subjective Effects
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
Investigators
Caroline A. Arout, Ph.D.
Research Scientist
New York State Psychiatric Institute
Eligibility Criteria
Inclusion Criteria
- •Male or non-pregnant female aged 21-53 years
- •Previous cannabis use
- •Previous opioid use
- •Urine test positive for recent cannabis use
- •Being able to perform all study procedures
- •Currently practicing an effective form of birth control (women only)
Exclusion Criteria
- •Meeting criteria for some Use Disorders
- •Report regular illicit drug use
- •If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process revealed any significant illness
Arms & Interventions
Placebo
Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
Intervention: Placebo
Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
Intervention: Oxycodone
Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
Intervention: Placebo
Cannabis (THC:CBD = ~1:0)
Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
Intervention: Placebo
Cannabis (THC:CBD = ~ 0:1)
Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
Intervention: Placebo
Cannabis (THC:CBD = ~ 1:1)
Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
Intervention: Placebo
Cannabis (THC:CBD = ~1:0) + Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
Intervention: Oxycodone
Cannabis (THC:CBD = ~ 0:1) + Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
Intervention: Oxycodone
Cannabis (THC:CBD = ~ 1:1) + Oxycodone
Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
Intervention: Oxycodone
Outcomes
Primary Outcomes
Subjective Effects
Time Frame: 6 weeks
Participants will rate "drug liking", "good drug effects", and "high" on a visual analogue scale (VAS; 1-100mm).
Cold Pressor Test
Time Frame: 6 weeks
Participants will immerse their hand in a bucket of ice water to determine pain threshold and pain tolerance latencies (in seconds).